Skip to main content
TipRanks
Go Ultimate75% OFF

Turn Therapeutics Inc (TTRX) Stock Price & Analysis

30 Followers

TTRX Stock Chart & Stats

$8.55$0.00(0.00%)
At close: 4:00 PM EST
$10$12.5$15Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$8.09 - $9.11
52-Week Range
$2.57 - $16.45
Previous Close
$8.55
Volume
N/A
Average Volume (3M)
98.74K
Market Cap
$261.40M
Enterprise Value
$429.54M
Total Cash (Recent Filing)
$10.36M
Total Debt (Recent Filing)
$490.55K
Price to Earnings (P/E)
―
Beta
0.55
Next Earnings
Apr 06, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

GX-03 Platform Differentiation

The proprietary PermaFusion platform and GX-03’s reported patient experience provide a potentially differentiated foundation in topical inflammatory and infectious disease therapies. If these characteristics remain supported through development, they could strengthen product positioning and expand applications across skin, nails, and mucous membranes.

Clinical Development Progress

Completion of the initial Phase 2 stage and progression into a larger optimized cohort demonstrate that GX-03 has advanced beyond early development. The defined efficacy endpoints and planned milestones create a clearer path for generating clinical evidence and potentially broadening the company’s dermatology pipeline.

Scientific Leadership

Adding an experienced physician-scientist with backgrounds in immunology, infectious disease, and public health may improve the quality of scientific and clinical decision-making. His role across multiple GX-03 indications could help coordinate the platform’s development strategy as the pipeline expands.

Bears Say

Pre-revenue Operating Model

Essentially no revenue combined with materially wider losses indicates that commercial traction has not yet emerged, while operating costs remain substantial. This leaves the company reliant on future development success before it can establish a self-sustaining earnings base or demonstrate durable operating leverage.

Persistent Cash Consumption

Ongoing and worsening negative cash flow means the business is consuming capital rather than funding its operations internally. Continued cash use can limit the resources available for clinical development and make financial stability increasingly dependent on successfully securing additional capital.

Dependence On External Funding

Reliance on external funding is a structural weakness while the company remains pre-revenue and loss-making. Until commercial traction develops, financing availability will remain important to sustaining research and operations, which can constrain strategic flexibility and increase execution pressure.

Turn Therapeutics Inc News

TTRX FAQ

What was Turn Therapeutics Inc’s price range in the past 12 months?
Turn Therapeutics Inc lowest stock price was $2.57 and its highest was $16.45 in the past 12 months.
What is Turn Therapeutics Inc’s market cap?
Turn Therapeutics Inc’s market cap is $261.40M.
When is Turn Therapeutics Inc’s upcoming earnings report date?
Turn Therapeutics Inc’s next earnings report is estimated for Apr 06, 2027 (not yet confirmed), which is in 138 days.
How were Turn Therapeutics Inc’s earnings last quarter?
Turn Therapeutics Inc released its earnings results on Nov 09, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.123.
Is Turn Therapeutics Inc overvalued?
According to Wall Street analysts Turn Therapeutics Inc’s price is currently Undervalued.
Does Turn Therapeutics Inc pay dividends?
Turn Therapeutics Inc does not currently pay dividends.
What is Turn Therapeutics Inc’s EPS estimate?
Turn Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Turn Therapeutics Inc have?
Turn Therapeutics Inc has 30,572,704 shares outstanding.
What happened to Turn Therapeutics Inc’s price movement after its last earnings report?
Turn Therapeutics Inc reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went up 3.27%.
Which hedge fund is a major shareholder of Turn Therapeutics Inc?
Hedge funds hold Turn Therapeutics Inc shares: the largest hedge-fund position in Turn Therapeutics Inc is 71,883,796 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology